EP0701445A1 - Agents contenant un compose a action anti-androgene ainsi qu'un compose a action competitive antagoniste de la progesterone - Google Patents

Agents contenant un compose a action anti-androgene ainsi qu'un compose a action competitive antagoniste de la progesterone

Info

Publication number
EP0701445A1
EP0701445A1 EP94918820A EP94918820A EP0701445A1 EP 0701445 A1 EP0701445 A1 EP 0701445A1 EP 94918820 A EP94918820 A EP 94918820A EP 94918820 A EP94918820 A EP 94918820A EP 0701445 A1 EP0701445 A1 EP 0701445A1
Authority
EP
European Patent Office
Prior art keywords
compound
hydroxy
methyl
prophylaxis
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP94918820A
Other languages
German (de)
English (en)
Inventor
Horst Michna
Martin Schneider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of EP0701445A1 publication Critical patent/EP0701445A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol

Definitions

  • the present invention relates to agents containing at least one compound with anti-androgenic (AA) and at least one compound with competitive, progesterone-gonistic (PA) activity. It relates in particular to agents of the specified type for the prophylaxis and treatment of prostate cancer and benign prostatic hyperplasia (BPH).
  • AA anti-androgenic
  • PA progesterone-gonistic
  • Prostatic hyperplasia is a benign enlargement of the prostate that begins with the so-called “inner” prostate.
  • the complaints are mainly due to the occurring obstructions of the urethra.
  • the emptying of the bladder is difficult and residual ham retardations occur. Without surgery, urea poisoning can occur.
  • the interstitium (stroma) and epithelium are involved to varying degrees in the enlargement of the prostate.
  • a shift in the estrogen / androgen ratio in favor of the estrogens can be regarded as the cause.
  • Various studies have shown that serum testosterone concentrations drop in older men; at the same time, the proportion of SHBG (sex hormone binding globuline, specific transport protein for steroids) increases, so that the bioavailability of androgens decreases even further.
  • Combinations of various anti-hormones or hormone synthesis inhibitors also belong to the prior art for the treatment of prostate hyperplasia, for example combination of an aromatase inhibitor with an anti-androgen (DE-A-31 21 152), an anti-estrogen with an anti-androgenic substance (DE-A- 28 17 157) or an aromatase inhibitor with a 5 ⁇ -reductase inhibitor (WO87 / 05216; WO91 / 00731; WO92 / 18132).
  • the object of the present invention is to provide medicaments which enable effective therapy of prostate carcinomas and, in general, also those which have become androgen-independent. At the same time, it would be desirable if such an agent were also suitable for the prophylaxis and therapy of benign prostatic hyperplasia.
  • Such drugs are provided by the present invention.
  • the agent according to the invention therefore has a synergistic effect for the indicated indications.
  • a (pharmaceutically active) combination containing AA and PA was not previously known.
  • the present invention also relates to the use of at least one compound with antiandrogenic (AA) and at least one compound with competitive, progesterone-antagonistic (PA) activity for the production of medicaments.
  • AA antiandrogenic
  • PA progesterone-antagonistic
  • the invention relates to the use of the abovementioned compounds for the production of medicaments for the prophylaxis and for the treatment of prostate carcinoma and for the prophylaxis and for the therapy of benign prostatic hyperplasia (BPH).
  • BPH benign prostatic hyperplasia
  • PA progesterone-antagonistic
  • the present invention therefore also relates to the use of at least one compound having a competitive, progesterone-antagonistic (PA) effect for the production of
  • PA progesterone-antagonistic
  • the weight ratio of the two components of the agent according to the invention can be varied within wide limits when used for the two indications described.
  • AA and PA are used together, separately, simultaneously and / or chronologically, in a weight ratio of 1:40 to 25: 1, preferably 1: 1 to 5: 1, and in particular 1: 1 to 2: 1. Co-administration is preferred.
  • Sequential treatment with the two components AA and PA of the combination according to the invention is also possible.
  • the component given as the second component can be given at any time after the component applied first, as long as it becomes bioavailable in the patient to be treated at the same time as an effective amount of the component applied first.
  • the antiandrogenic component can be given first and then the PA component.
  • the treatment regimen for a patient suffering from prostate cancer or BPH can also be such that monotherapy with an antiandrogen is carried out as the first treatment measure, over a period of several weeks until no further growth inhibition of prostate cancer is achieved. This is followed by treatment with PA alone or AA and PA in combination, simultaneously or sequentially.
  • AA and PA are administered in one dose unit or in separate dose units.
  • All compounds which act as competitive antiandrogens i.e. those that mediate their AA effect through strong affinity for the androgen receptor.
  • These AA-acting compounds can be of both steroidal origin and non-steroids.
  • Suitable steroids are the compounds of the general formulas I and II:
  • Rl and R ⁇ each like a hydrogen atom or both: »m another carbon-carbon bond or the methyl group ⁇ : - .
  • R-3 is the acyl radical of an acid customary in steroid chemistry
  • Y is an oxygen atom or the group H, OR4 with R ⁇ in the meaning of hydrogen, acyl or alkyl,
  • Xl is a hydrogen or chlorine atom
  • X2 is a hydrogen, fluorine or chlorine atom
  • R * and R ⁇ each stand for hydrogen or both together the methylene group, X hydrogen, fluorine or chlorine and
  • R 3 and R 4 represent the residue of an acid customary in steroid chemistry.
  • acyl residue should be understood to mean the residues of the acids customary in steroid chemistry for the esterification of secondary and tertiary hydroxyl groups.
  • Aliphatic carboxylic acids having 1 to 8 carbon atoms are preferred, such as, for example, acetic acid, propionic acid, butyric acid, valeric acid, isovaleric acid, caproic acid, oenanthic acid, etc.
  • the esters of acetic acid are particularly preferred.
  • Alkyl is to be understood as meaning lower alkyl groups with 1-5 carbon atoms, the methyl group being preferred.
  • Typical compounds of general formula I are the 17-esters of, for example
  • Typical compounds of the general formula II are, for example, 6-chloro-17ass-acetoxy-17a ⁇ -methyl-1,2, 2-methylene-D-homo-4,6-androstadiene-3J7-dione and 6-chloro-17 ⁇ -acetoxy-17ß -methyl-l, 2 ⁇ -methylene-D-homo-4,6-androstadiene-3J7a-dione.
  • nonsteroidal antiandrogens are the compounds 2-methyl-N- [4-nitro-3- (trifluoromethyl) phenyl] propionamide (flutamide)
  • 5 ⁇ -reductase inhibitors which prevent the conversion of testosterone into dihydrotestosterone are also suitable according to the invention as a compound with an AA effect.
  • the compounds with antiandrogenic activity are administered in amounts of about 1 to 500 mg of cyproterone acetate, preferably 50 to 500 mg, per day or an equivalent amount of another antiandrogen.
  • the dosage of the compounds with a competitive progesterone-antagonistic effect for the indications prostate cancer and benign prostatic hyperplasia is 20 - 200 mg onapristone per day or an equivalent amount of another compound with PA effect.
  • the active ingredients can be processed with the additives, carrier substances and / or taste correctives customary in pharmaceutical pharmacy to methods customary in conventional methods.
  • Tablets, coated tablets, capsules, pills, suspensions or solutions are particularly suitable for the preferred oral application.
  • Oily solutions such as sesame oil or castor oil solutions are suitable for parenteral, in particular intramuscular, application.
  • Solubilizers such as, for example, benzyl benzoate or benzyl alcohol, can be added to increase the solubility.
  • the medicinal products formulated as above preferably contain 10 mg to 100 mg of onapristone and 50 mg to 100 mg of cyproterone acetate, or in each case the equivalent doses of another competitive progesterone antagonist and antiandrogen.
  • composition of an AA tablet for oral administration Composition of an AA tablet for oral administration
  • composition of a PA tablet for oral administration Composition of a PA tablet for oral administration
  • composition of an AA / PA tablet for oral administration Composition of an AA / PA tablet for oral administration
  • a tablet press is manufactured. If appropriate, the active compounds according to the invention, each with half of the additives indicated above, can also be pressed separately into a two-layer tablet.
  • the tumor-inhibiting effect of the agent according to the invention is checked on the androgen-dependent R3327H prostate carcinoma of the rat:
  • the R3327H prostate carcinoma was found as a spontaneous tumor in the dorsal prostate of a Copenhagen (Cop) rat and further transplanted.
  • the tumor is androgen dependent, i.e. Castration of animals with established tumors almost completely inhibits tumor growth. After a few months, however, there is renewed growth (so-called "relapse").
  • the R3327H tumor contains androgen and estrogen receptors as well as 5 ⁇ -reductase. It is very similar in its response to antiandrogens, estrogens or LHRH analogues and histologically to human prostate carcinoma and is therefore an almost ideal tumor model for the development of new prostate carcinoma therapeutics.
  • test substances are dissolved in benzyl benzoate + castor oil (1 + 4) and the single dose in a volume of 0J ml / 100 body weight s.c. or p.o. applied.
  • test substance is suspended in a carrier liquid (85 mg myrj in 100 ml 0.9% w / v NaCl solution) and the daily dose is administered in a volume of 0J mg / 100 g body weight.
  • a carrier liquid 85 mg myrj in 100 ml 0.9% w / v NaCl solution
  • the daily dose is administered in a volume of 0J mg / 100 g body weight.
  • Therapy is started with a tumor size of 10 - 25 mm ⁇ (approx. 8 to 10 weeks after implantation) and carried out 6 times a week for 6 to 8 weeks.
  • Tumor fragments with an edge length of 2 mm are implanted inguinal sc on both sides of intact rats. Depending on the growth of the tumor, new strain maintenance is started every 4-6 months.
  • At least 3 different tumors are removed from the pedigree, cut into pieces with an edge length of 2 mm and implanted as described above.
  • the rats are randomized to groups of 7-10 animals. One group is castrated to control androgen dependence at the start of therapy. Tumor growth is determined by determining the area of the tumor using a caliper. The tumor area is calculated from the product of the longest and the perpendicular diameter of the tumor.
  • the animals are killed, the tumors. Prostate, seminal vesicles and testicles prepared and weighed.
  • Average values + SE of tumor areas, tumor weights and possibly organ weights are determined. The growth course of the tumors is shown graphically.
  • the statistical evaluation is carried out using the Dunnett test.
  • the observed tumor growth inhibition or remission of the tumors when treated with the agent according to the invention is superior to that of the sum of the respective monotherapy with AA and PA.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Des agents contiennent au moins un composé à action anti-androgène (AA) ainsi qu'au moins un composé à action compétitive antagoniste de la progestérone (AP). Ces agents sont utiles pour préparer des médicaments pour la prophylaxie et la thérapie de carcinomes de la prostate ainsi que de l'hyperplasie bénigne de la prostate (HBP). L'invention concerne en outre l'utilisation d'au moins un composé à action AP afin de préparer des médicaments pour la prophylaxie et la prévention de l'HBP.
EP94918820A 1993-05-28 1994-05-30 Agents contenant un compose a action anti-androgene ainsi qu'un compose a action competitive antagoniste de la progesterone Withdrawn EP0701445A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4318371 1993-05-28
DE19934318371 DE4318371A1 (de) 1993-05-28 1993-05-28 Mittel, enthaltend eine Verbindung mit antiandrogener sowie eine Verbindung mit kompetitiver, progesteronantagonistischer Wirkung
PCT/EP1994/001756 WO1994027610A1 (fr) 1993-05-28 1994-05-30 Agents contenant un compose a action anti-androgene ainsi qu'un compose a action competitive antagoniste de la progesterone

Publications (1)

Publication Number Publication Date
EP0701445A1 true EP0701445A1 (fr) 1996-03-20

Family

ID=6489489

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94918820A Withdrawn EP0701445A1 (fr) 1993-05-28 1994-05-30 Agents contenant un compose a action anti-androgene ainsi qu'un compose a action competitive antagoniste de la progesterone

Country Status (5)

Country Link
EP (1) EP0701445A1 (fr)
AU (1) AU6998494A (fr)
CA (1) CA2163878A1 (fr)
DE (1) DE4318371A1 (fr)
WO (1) WO1994027610A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2181358A1 (fr) * 1994-01-21 1995-07-27 Nancy M. Gray Procedes et compositions de traitement de maladies dependantes des androgenes a l'aide de r-(-)-casodex optiquement pur
DE19825591A1 (de) * 1998-06-09 1999-12-23 Jenapharm Gmbh Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata
UY27301A1 (es) * 2001-05-25 2003-02-28 Schering Ag Uso y composiciones de antiprogestinas para el tratamiento de enfermedades de la próstata
SE0103838D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE230994T1 (de) * 1989-07-07 2003-02-15 Endorech Inc Methode zur behandlung androgenbedingter krankheiten
DE4039561A1 (de) * 1990-12-07 1992-07-09 Schering Ag Verwendung von antigestagenen zur herstellung von arzneimitteln

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9427610A1 *

Also Published As

Publication number Publication date
DE4318371A1 (de) 1994-12-01
AU6998494A (en) 1994-12-20
WO1994027610A1 (fr) 1994-12-08
CA2163878A1 (fr) 1994-12-08

Similar Documents

Publication Publication Date Title
DE3121152C2 (fr)
DE69532894T2 (de) Verfahren zur empfängnisverhütung
DE69033020T2 (de) Kombinationstherapie zur prophylaxe und/oder behandlung benigner prostatahyperplasie
EP0310541B1 (fr) Composés antigestagéniques et anti-oestrogéniques pour le déclenchement de la naissance et pour l'interruption de la grossesse ainsi que pour le traitement des troubles gynécologiques
DE69034035T2 (de) Methode zur behandlung androgenbedingter krankheiten
DE60216630T2 (de) Verwendung von östrogen in kombination mit progestogen für die hormonsubstitutiionstherapie
US4310523A (en) Combined antiestrogens and antigonadotropically effective antiandrogens for the prophylaxis and therapy of hyperplasia of the prostate
DE69022722T2 (de) Kombinationstherapie zur behandlung von estrogenempfindlichen erkrankungen.
DE19739916C2 (de) Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
DE68917219T2 (de) Therapeutisches Erzeugnis zur Behandlung von Beschwerden während der oder nach den Wechseljahren.
EP0723439A1 (fr) Combinaison d'antagonistes de la progesterone et d'anti- strogenes a action partiellement agoniste pour l'hormonotherapie substitutive des femmes peri et postmenopausees
WO2013064620A1 (fr) 18-méthyl-6,7-méthylène-3-oxo-17-prégn-4-ène-21,17β-carbolactones, préparations pharmaceutiques contenant ces composés et leur utilisation dans le traitement de l'endométriose
EP0799042A1 (fr) Composes a action antagoniste de la progesterone et anti strogene utilisees conjointement pour la contraception feminine
CH648485A5 (de) Mittel zur prophylaxe und therapie der prostatahyperplasie.
DE60318447T2 (de) Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung
EP0310542B1 (fr) Composés antigestagéniques et anti-oestrogéniques pour le traitement des tumeurs dépendant des hormones
DE602004009288T2 (de) Verwendung einer kombination eines aromatasehemmers, eines progestins und eines oestrogens zur behandlung von endometriose
WO1997032588A2 (fr) Association de dehydro-epiandrosterone et d'inhibiteurs de l'aromatase et utilisation de cette association pour produire un medicament en vue de traiter une carence relative et absolue en androgenes chez l'homme
WO1994027610A1 (fr) Agents contenant un compose a action anti-androgene ainsi qu'un compose a action competitive antagoniste de la progesterone
WO1987005216A1 (fr) COMBINAISON D'INHIBITEURS D'AROMATASE ET D'INHIBITEURS DE 5alpha-REDUCTASE
DE3339295C2 (fr)
WO2002074315A1 (fr) Preparations pharmaceutiques combinees renfermant des inhibiteurs de l'aromatase et des substances a activite oestrogenique et leur utilisation dans la production d'un medicament pour l'oestrogenotherapie de substitution
WO1995005828A1 (fr) Composes a action antagoniste de la progesterone et anti-×strogene pour la therapie de liomyomes uterins
DE19510862A1 (de) Verwendung von Antiestrogenen zur männlichen Fertilitätskontrolle
DE10134768A1 (de) Pharmazeutische Kombinationspräparate enthaltend Aromatasehemmer und Substanzen mit estrogener Wirkung sowie ihre Verwendung

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19951213

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19980320